Lysergic acid diethylamide is under clinical development by Mind Medicine MindMed and currently in Phase II for Major Depressive Disorder.

If you or a loved one is struggling with anxiety or depression, contact the Substance Abuse and Mental Health Services Administration (SAMHSA) National Helpline at 800-662-4357 for information on ...

The differential diagnosis among these and with regard to other disorders with similar symptom features remains the foundation for treatment ... depressive symptoms without manic, mixed, or major ...

The most-read articles addressing mental health in 2024 spanned therapeutic advancements, research discoveries, and insight ...

b For adolescents with major depressive disorder or if OCD, posttraumatic stress disorder, or generalized anxiety disorder is present. c First-line treatment if drug interactions with fluoxetine ...

Despite these changes, homosexuality was still described as a "sexual disorder not otherwise specified," while "mental retardation" was still used to describe people with intellectual disabilities.

Depression is a heterogeneous group of conditions and a clinical diagnosis without external validators. Diagnosis of depression in the setting of disorders that produce psychomotor retardation and ...

Samelisant (SUVNG-3031) is under development for the treatment of narcolepsy with and without cataplexy and cognitive disorders. The drug candidate is administered orally in the form of tablet. The ...

Self assessed intensity of symptoms: before, 23.2 (7); after, 17.7 (8.1); p = 0.006. Values are mean (SD)). Subjective and objective changes in depression scores correlated strongly (r = 0.66, p = ...

Nearly every global society governing women’s health recommends screening adult women for incontinence. It seldom happens.

You can create a release to package software, along with release notes and links to binary files, for other people to use. Learn more about releases in our docs.